Miwei Bio (688062.SH) announced that the company has developed innovative drugs 9MW2821 with independent intellectual property rights...
According to the announcement of the Zhitong Finance APP, Miwei Bio (688062.SH) stated that the innovative drug 9MW2821 developed with independent intellectual property rights is currently undergoing multiple clinical studies for multiple indications such as urinary tract epithelial carcinoma, cervical cancer, esophageal cancer, and breast cancer. Recently, 9MW2821 has been included in the list of breakthrough therapies by the National Medical Products Administration Drug Evaluation Center (referred to as the “Drug Evaluation Center”), and is used to treat locally advanced or metastatic urinary tract epithelial carcinoma that has failed previous platinum-based chemotherapy and PD-(L)1 inhibitor treatment, and has been publicly listed.